David Martin
David Martin has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
- Andre B. Araujo
Moderna, 200 Technology Square, Cambridge, MA 02139, USA
2 shared publications Tianyi Lu
Moderna, Inc. , Cambridge, Massachusetts
2 shared publicationsA. A. Luft
1 shared publication- Adi Idris
Centre for Immunology and Infection Control, School of Biomedical Sciences, Queensland University of Technology
1 shared publication - Ahreej Eltayeb
Moderna, Cambridge, MA, United States
1 shared publication - Alexander Muir Walker
From theDivision of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
1 shared publication
Latest Publications
- Open Access
- 29 August 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (9)
Incidence and Burden of Respiratory Syncytial Virus-Associated Hospitalizations Among People 65 and Older in France: A National Hospital Database Study
Background: Respiratory Syncytial Virus (RSV) presents a serious threat to older adults, particularly those with chronic conditions, and may lead to severe issues. Hospitalizations are frequently underreported due to diagnostic challenges and a lack of standardized testing. This study estimates national-level RSV hospitalization rates and examines the clinical and economic burden in high-risk elderly populations in France. Method: RSV-coded hospitalizations (2017–2022) were identified using the French National Hospital Discharge database. A correction factor, derived from virological data from two local hospitals, was applied to adjust for under-reporting. Incidence rates were calculated using demographic data, focusing on adults aged 75+ and high-risk individuals aged 65–74 with comorbidities. Hospitalization characteristics and costs were also analyzed. Results: For adults aged 75+, the adjusted incidence of RSV hospitalizations ranged from 85 to 221 per 100,000. Inpatient mortality was 8.9%–10.4%, and annual adjusted costs ranged from €27 to €76 million, with intensive care units (ICU) admissions contributing heavily. High-risk adults aged 65–74 had higher adjusted incidence rates (161–735 per 100,000), along with increased ICU admission rates and disproportionately higher costs due to intensive care needs. Conclusions: The significant burden of RSV on adults aged 75+ and high-risk adults aged 65–74 with chronic conditions remains underreported. Improved diagnostics and targeted vaccination programs are essential to reduce hospitalizations, mortality, and healthcare costs in these vulnerable groups.
- 29 August 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (9)
Open AccessIncidence and Burden of Respiratory Syncytial Virus-Associated Hospitalizations Among People 65 and Older in France: A National Hospital Database Study
Background: Respiratory Syncytial Virus (RSV) presents a serious threat to older adults, particularly those with chronic conditions, and may lead to severe issues. Hospitalizations are frequently underreported due to diagnostic challenges and a lack of standardized testing. This study estimates national-level RSV hospitalization rates and examines the clinical and economic burden in high-risk elderly populations in France. Method: RSV-coded hospitalizations (2017–2022) were identified using the French National Hospital Discharge database. A correction factor, derived from virological data from two local hospitals, was applied to adjust for under-reporting. Incidence rates were calculated using demographic data, focusing on adults aged 75+ and high-risk individuals aged 65–74 with comorbidities. Hospitalization characteristics and costs were also analyzed. Results: For adults aged 75+, the adjusted incidence of RSV hospitalizations ranged from 85 to 221 per 100,000. Inpatient mortality was 8.9%–10.4%, and annual adjusted costs ranged from €27 to €76 million, with intensive care units (ICU) admissions contributing heavily. High-risk adults aged 65–74 had higher adjusted incidence rates (161–735 per 100,000), along with increased ICU admission rates and disproportionately higher costs due to intensive care needs. Conclusions: The significant burden of RSV on adults aged 75+ and high-risk adults aged 65–74 with chronic conditions remains underreported. Improved diagnostics and targeted vaccination programs are essential to reduce hospitalizations, mortality, and healthcare costs in these vulnerable groups.
- Open Access
- 22 January 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14 (1) , e60669
Clinical Characteristics of Virologically Confirmed Respiratory Syncytial Virus in English Primary Care: Protocol for an Observational Study of Acute Respiratory Infection
Background: There are gaps in our understanding of the clinical characteristics and disease burden of the respiratory syncytial virus (RSV) among community-dwelling adults. This is in part due to a lack of routine testing at the point of care. More data would enhance our assessment of the need for an RSV vaccination program for adults in the United Kingdom. Objective: This study aimed to implement point-of-care-testing (POCT) in primary care to describe the incidence, clinical presentation, risk factors, and economic burden of RSV among adults presenting with acute respiratory infection. Methods: We are recruiting up to 3600 patients from at least 21 practices across England to participate in the Royal College of General Practitioners Research Surveillance Centre. Practices are selected if they undertake reference virology sampling for the Royal College of General Practitioners Research Surveillance Centre and had previous experience with respiratory illness studies. Any adult, ≥40 years old, presenting with acute respiratory infection with onset ≤10 days, but without RSV within the past 28 days, will be eligible to participate. We will estimate the incidence proportion of RSV, describe the clinical features, and risk factors of patients with RSV infection, and measure the economic burden of RSV infection. Results: A total of 25 practices across different English health administrative regions expressed interest and were recruited to participate. We have created and tested an educational program to deploy POCT for RSV in primary care. In addition to using the POCT device, we provide suggestions about how to integrate POCT into primary care workflow and templates for high-quality data recording of diagnosis, symptoms, and signs. In the 2023-2024 winter RSV detection in the sentinel network grew between October and late November. According to data from the UK Health Security Agency, the peak RSV swab positivity was in International Standards Organization week 48, 2023. Data collection remains ongoing, and results from the subset of practices participating in this study are not yet available. Conclusions: This study will provide data on the RSV incidence in the community as well as rapid information to inform sentinel surveillance and vaccination programs. This information could potentially improve clinical decision-making. International Registered Report Identifier (IRRID): DERR1-10.2196/60669
- 22 January 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14 (1) , e60669
Open AccessClinical Characteristics of Virologically Confirmed Respiratory Syncytial Virus in English Primary Care: Protocol for an Observational Study of Acute Respiratory Infection
Background: There are gaps in our understanding of the clinical characteristics and disease burden of the respiratory syncytial virus (RSV) among community-dwelling adults. This is in part due to a lack of routine testing at the point of care. More data would enhance our assessment of the need for an RSV vaccination program for adults in the United Kingdom. Objective: This study aimed to implement point-of-care-testing (POCT) in primary care to describe the incidence, clinical presentation, risk factors, and economic burden of RSV among adults presenting with acute respiratory infection. Methods: We are recruiting up to 3600 patients from at least 21 practices across England to participate in the Royal College of General Practitioners Research Surveillance Centre. Practices are selected if they undertake reference virology sampling for the Royal College of General Practitioners Research Surveillance Centre and had previous experience with respiratory illness studies. Any adult, ≥40 years old, presenting with acute respiratory infection with onset ≤10 days, but without RSV within the past 28 days, will be eligible to participate. We will estimate the incidence proportion of RSV, describe the clinical features, and risk factors of patients with RSV infection, and measure the economic burden of RSV infection. Results: A total of 25 practices across different English health administrative regions expressed interest and were recruited to participate. We have created and tested an educational program to deploy POCT for RSV in primary care. In addition to using the POCT device, we provide suggestions about how to integrate POCT into primary care workflow and templates for high-quality data recording of diagnosis, symptoms, and signs. In the 2023-2024 winter RSV detection in the sentinel network grew between October and late November. According to data from the UK Health Security Agency, the peak RSV swab positivity was in International Standards Organization week 48, 2023. Data collection remains ongoing, and results from the subset of practices participating in this study are not yet available. Conclusions: This study will provide data on the RSV incidence in the community as well as rapid information to inform sentinel surveillance and vaccination programs. This information could potentially improve clinical decision-making. International Registered Report Identifier (IRRID): DERR1-10.2196/60669
- Open Access
- 26 November 2024
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (12) , ofae695
Effectiveness of the 2023–2024 Omicron XBB.1.5-containing mRNA COVID-19 Vaccine (mRNA-1273.815) in Preventing COVID-19–related Hospitalizations and Medical Encounters Among Adults in the United States
This study aimed to evaluate the vaccine effectiveness (VE) of mRNA-1273.815, a 2023-2024 Omicron XBB.1.5-containing mRNA COVID-19 vaccine, at preventing COVID-19-related hospitalizations and any medically attended COVID-19 in adults. In a linked EHR-claims dataset, we identified US adults (≥18 years) who received the mRNA-1273.815 vaccine (exposed cohort) between September 12 and December 15, 2023, matched 1:1 to individuals who did not receive a 2023-2024 updated COVID-19 vaccine (unexposed cohort). Cohorts were balanced using inverse probability of treatment weighting on demographics, vaccination and infection history, and underlying medical conditions. Study cohorts were followed until December 31, 2023 for COVID-19-related hospitalizations and medically attended COVID-19. Cox regression was used to estimate hazard ratios (HR) and VE. Subgroup analyses were performed for adults ≥50, adults ≥65, and individuals with underlying medical conditions. Overall, 859,335 matched pairs of mRNA-1273.815 recipients and unexposed adults were identified. The mean (SD) age was 63 (16) years. More than 60% of individuals in both cohorts had an underlying medical condition. Among the overall adult population, VE was 60.2% (95% CI: 53.4-66.0%) against COVID-19-related hospitalization and 33.1% (30.2%-35.9%) against medically attended COVID-19 over a median follow-up of 63 (IQR: 44-78) days. VE estimates by age and underlying medical conditions were similar. These results demonstrate the significant protection provided by mRNA-1273.815 against COVID-19-related hospitalizations and any medically attended COVID-19 in adults, regardless of vaccination history, and support CDC recommendations to stay up-to-date with COVID-19 vaccination to prevent COVID-19-related outcomes, including hospitalizations.
- 26 November 2024
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (12) , ofae695
Open AccessEffectiveness of the 2023–2024 Omicron XBB.1.5-containing mRNA COVID-19 Vaccine (mRNA-1273.815) in Preventing COVID-19–related Hospitalizations and Medical Encounters Among Adults in the United States
This study aimed to evaluate the vaccine effectiveness (VE) of mRNA-1273.815, a 2023-2024 Omicron XBB.1.5-containing mRNA COVID-19 vaccine, at preventing COVID-19-related hospitalizations and any medically attended COVID-19 in adults. In a linked EHR-claims dataset, we identified US adults (≥18 years) who received the mRNA-1273.815 vaccine (exposed cohort) between September 12 and December 15, 2023, matched 1:1 to individuals who did not receive a 2023-2024 updated COVID-19 vaccine (unexposed cohort). Cohorts were balanced using inverse probability of treatment weighting on demographics, vaccination and infection history, and underlying medical conditions. Study cohorts were followed until December 31, 2023 for COVID-19-related hospitalizations and medically attended COVID-19. Cox regression was used to estimate hazard ratios (HR) and VE. Subgroup analyses were performed for adults ≥50, adults ≥65, and individuals with underlying medical conditions. Overall, 859,335 matched pairs of mRNA-1273.815 recipients and unexposed adults were identified. The mean (SD) age was 63 (16) years. More than 60% of individuals in both cohorts had an underlying medical condition. Among the overall adult population, VE was 60.2% (95% CI: 53.4-66.0%) against COVID-19-related hospitalization and 33.1% (30.2%-35.9%) against medically attended COVID-19 over a median follow-up of 63 (IQR: 44-78) days. VE estimates by age and underlying medical conditions were similar. These results demonstrate the significant protection provided by mRNA-1273.815 against COVID-19-related hospitalizations and any medically attended COVID-19 in adults, regardless of vaccination history, and support CDC recommendations to stay up-to-date with COVID-19 vaccination to prevent COVID-19-related outcomes, including hospitalizations.
- Open Access
- 4 September 2020
- Published by Oxford University Press (OUP) in Journal of the American Medical Informatics Association
- Vol. 27 (11) , 1808-1812
Recommendations for patient similarity classes: results of the AMIA 2019 workshop on defining patient similarity
Defining patient-to-patient similarity is essential for the development of precision medicine in clinical care and research. Conceptually, the identification of similar patient cohorts appears straightforward; however, universally accepted definitions remain elusive. Simultaneously, an explosion of vendors and published algorithms have emerged and all provide varied levels of functionality in identifying patient similarity categories. To provide clarity and a common framework for patient similarity, a workshop at the American Medical Informatics Association 2019 Annual Meeting was convened. This workshop included invited discussants from academics, the biotechnology industry, the FDA, and private practice oncology groups. Drawing from a broad range of backgrounds, workshop participants were able to coalesce around 4 major patient similarity classes: (1) feature, (2) outcome, (3) exposure, and (4) mixed-class. This perspective expands into these 4 subtypes more critically and offers the medical informatics community a means of communicating their work on this important topic.
- 4 September 2020
- Published by Oxford University Press (OUP) in Journal of the American Medical Informatics Association
- Vol. 27 (11) , 1808-1812
Open AccessRecommendations for patient similarity classes: results of the AMIA 2019 workshop on defining patient similarity
Defining patient-to-patient similarity is essential for the development of precision medicine in clinical care and research. Conceptually, the identification of similar patient cohorts appears straightforward; however, universally accepted definitions remain elusive. Simultaneously, an explosion of vendors and published algorithms have emerged and all provide varied levels of functionality in identifying patient similarity categories. To provide clarity and a common framework for patient similarity, a workshop at the American Medical Informatics Association 2019 Annual Meeting was convened. This workshop included invited discussants from academics, the biotechnology industry, the FDA, and private practice oncology groups. Drawing from a broad range of backgrounds, workshop participants were able to coalesce around 4 major patient similarity classes: (1) feature, (2) outcome, (3) exposure, and (4) mixed-class. This perspective expands into these 4 subtypes more critically and offers the medical informatics community a means of communicating their work on this important topic.
- 1 November 2018
- Published by Elsevier in Oral Oncology
- Vol. 86, 105-112
Aurora kinases are a novel therapeutic target for HPV-positive head and neck cancers
- 1 November 2018
- Published by Elsevier in Oral Oncology
- Vol. 86, 105-112
Aurora kinases are a novel therapeutic target for HPV-positive head and neck cancers
- 5 March 2018
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 27 (7) , 707-712
Sequential surveillance for drug safety in a regulatory environment
- 5 March 2018
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 27 (7) , 707-712
Sequential surveillance for drug safety in a regulatory environment
- 9 May 2013
- Published by Springer Nature in Drug Safety
- Vol. 36 (7) , 547-556
Data Mining for Prospective Early Detection of Safety Signals in the Vaccine Adverse Event Reporting System (VAERS): A Case Study of Febrile Seizures after a 2010–2011 Seasonal Influenza Virus Vaccine
Reports of data mining results as an initial indication of a prospectively detected safety signal in the US Vaccine Adverse Event Reporting System (VAERS) have been limited. In April 2010 a vaccine safety signal for febrile seizures after Fluvax® and Fluvax® Junior was identified in Australia without the aid of data mining. In order to refine Northern Hemisphere influenza vaccine safety surveillance, VAERS data mining analyses based on vaccine brand name were initiated during the 2010–2011 influenza season.
- 9 May 2013
- Published by Springer Nature in Drug Safety
- Vol. 36 (7) , 547-556
Data Mining for Prospective Early Detection of Safety Signals in the Vaccine Adverse Event Reporting System (VAERS): A Case Study of Febrile Seizures after a 2010–2011 Seasonal Influenza Virus Vaccine
Reports of data mining results as an initial indication of a prospectively detected safety signal in the US Vaccine Adverse Event Reporting System (VAERS) have been limited. In April 2010 a vaccine safety signal for febrile seizures after Fluvax® and Fluvax® Junior was identified in Australia without the aid of data mining. In order to refine Northern Hemisphere influenza vaccine safety surveillance, VAERS data mining analyses based on vaccine brand name were initiated during the 2010–2011 influenza season.
- 1 January 2002
- Published by Association for Computational Linguistics (ACL)
- p. 619-620
Working hard in the 'office'
- 1 January 2002
- Published by Association for Computational Linguistics (ACL)
- p. 619-620
Working hard in the 'office'
- Open Access
- 1 June 2000
- Published by Office of Scientific and Technical Information (OSTI)
In Summary: Idaho National Engineering and Environmental Laboratory Site Environmental Report for Calendar Year 1998
Scientists from the Environmental Science and Research Foundation, Lockheed Martin Idaho Technologies Company (LMITCO), the US Geological Survey, the Naval Nuclear Propulsion Program Naval Reactors Facility, Argonne National Laboratory-West, and others monitored the environment on and around the INEEL to find contaminants attributable to the INEEL. During 1998, exposures from the INEEL to the public were found to be negligible. The US Department of Energy (DOE) and LMITCO made progress in developing and implementing a site-wide Environmental Management System. This system provides an underlying structure to make the management of environmental activities at the INEEL more systematic and predictable. Pathways by which INEEL contaminants might reach people off the INEEL were monitored. These included air, precipitation, water, locally grown food (milk, lettuce, wheat, and potatoes), livestock, game animals, soil, and direct ionizing radiation. Results from samples collected to monitor these pathways often contain ''background radioactivity,'' which is radioactivity from natural sources and nuclear weapons tests carried out between 1945 and 1980. According to results obtained in 1998, radioactivity from operations at the INEEL could not be distinguished from this background radioactivity in the regions surrounding the INEEL. Because radioactivity from the INEEL was not detected by offsite environmental surveillance methods,more » computer models were used to estimate the radiation dose to the public. The hypothetical maximum dose to an individual from INEEL operations was calculated to be 0.08 millirem. That is 0.002 percent of an average person's annual dose of 360 millirem from natural background radiation in southeast Idaho. « less
- 1 June 2000
- Published by Office of Scientific and Technical Information (OSTI)
Open AccessIn Summary: Idaho National Engineering and Environmental Laboratory Site Environmental Report for Calendar Year 1998
Scientists from the Environmental Science and Research Foundation, Lockheed Martin Idaho Technologies Company (LMITCO), the US Geological Survey, the Naval Nuclear Propulsion Program Naval Reactors Facility, Argonne National Laboratory-West, and others monitored the environment on and around the INEEL to find contaminants attributable to the INEEL. During 1998, exposures from the INEEL to the public were found to be negligible. The US Department of Energy (DOE) and LMITCO made progress in developing and implementing a site-wide Environmental Management System. This system provides an underlying structure to make the management of environmental activities at the INEEL more systematic and predictable. Pathways by which INEEL contaminants might reach people off the INEEL were monitored. These included air, precipitation, water, locally grown food (milk, lettuce, wheat, and potatoes), livestock, game animals, soil, and direct ionizing radiation. Results from samples collected to monitor these pathways often contain ''background radioactivity,'' which is radioactivity from natural sources and nuclear weapons tests carried out between 1945 and 1980. According to results obtained in 1998, radioactivity from operations at the INEEL could not be distinguished from this background radioactivity in the regions surrounding the INEEL. Because radioactivity from the INEEL was not detected by offsite environmental surveillance methods,more » computer models were used to estimate the radiation dose to the public. The hypothetical maximum dose to an individual from INEEL operations was calculated to be 0.08 millirem. That is 0.002 percent of an average person's annual dose of 360 millirem from natural background radiation in southeast Idaho. « less